Oral hormonal contraceptives have been available since the early 1960s when Pincus and Rock found that norethynodrel (9.65 mg) in combination with mestranol (150 μg) inhibited ovulation and provided sufficient control of the menstrual cycle. Since then, different approaches to contraception have been pursued. Hormonal steroids can either act as ovulation inhibitors or prevent conception by altering the cervical mucus.
KeywordsCholesterol Estrogen Triglyceride Renin Acne
Unable to display preview. Download preview PDF.
- Hahn DW, McGuire JL, Cohn RM, Beck LR, Tice TR, Lewis DH (1984) Development of microencapsulated norgestimate as a long-acting contraceptive. In: Zatuchni GI, Mishell DR, Shoupe D, Goldsmith A, Shelton JD, Sciarra J J (eds) Long-acting contraceptive delivery systems. Harper and Row, Philadelphia, pp 96–112Google Scholar
- Juzpe AA (1984) Postcoital contraception. Clin Obstet and Gynaecol 11:787–797Google Scholar
- Population Reports (1987) Injectables and implants. Popul Rep 3Google Scholar
- Shoupe D, Spitz I, Osborn C, Page MA, Mishell DR Jr, Lobo RA (1986) Effects of progesterone (P) antagonists on gonadotropins at midcycle and during the luteal phase. In: Society for gynecologic investigation, Toronto, Ontario, Canada, 19–22 March 1986, abstract 40Google Scholar
- Skouby SO (1987) Oral contraceptives and diabetes mellitus. Gynecol Endocrinol (Suppl) 2:30Google Scholar
- Van Santen MR (1987) Postcoital interception and contragestion. Elinkwijk, UtrechtGoogle Scholar